Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Hirohashi Y, Furuhata T, Takemasa I, Patel P, Vora H, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Yoshino T, Taniguchi H, Bifulco C, Lugli A, Lee JKJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi P, Roehrl MH, Ohashi PS, Nguyen LT, Han SJ, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson E, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Marliot F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, Van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Marincola FM, Ascierto PA, Fox BA, Pagès F, Kawakami Y, Galon J (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 14

Article Number: 4346

Journal Issue: 18

DOI: 10.3390/cancers14184346

Abstract

BACKGROUND: In this study, we evaluated the prognostic value of Immunoscore in patients with stage I–III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I–III CC. METHODS: CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS). RESULTS: Immunoscore stratified Asian patients (n = 423) into different risk categories and was not impacted by age. Recurrence-free rates at 3 years were 78.5%, 85.2%, and 98.3% for a Low, Intermediate, and High Immunoscore, respectively (HR[Low-vs-High] = 7.26 (95% CI 1.75−30.19); p = 0.0064). A High Immunoscore showed a significant association with prolonged TTR, OS, and DFS (p < 0.05). In Cox multivariable analysis stratified by center, Immunoscore association with TTR was independent (HR[Low-vs-Int+High] = 2.22 (95% CI 1.10–4.55) p = 0.0269) of the patient’s gender, T-stage, N-stage, sidedness, and MSI status. A significant association of a High Immunoscore with prolonged TTR was also found among MSS (HR[Low-vs-Int+High] = 4.58 (95% CI 2.27−9.23); p ≤ 0.0001), stage II (HR[Low-vs-Int+High] = 2.72 (95% CI 1.35−5.51); p = 0.0052), low-risk stage-II (HR[Low-vs-Int+High] = 2.62 (95% CI 1.21−5.68); p = 0.0146), and high-risk stage II patients (HR[Low-vs-Int+High] = 3.11 (95% CI 1.39−6.91); p = 0.0055). CONCLUSION: A High Immunoscore is significantly associated with the prolonged survival of CC patients within the Asian population.

Authors with CRIS profile

Involved external institutions

Universität Bern Switzerland (CH) National Cancer Center Hospital East / 国立がん研究センター東病院 Japan (JP) Cliniques universitaires Saint-Luc (CHU St-Luc) Belgium (BE) King Albert II Cancer Institute Belgium (BE) Gujarat Cancer & Research Institute India (IN) University of Texas MD Anderson Cancer Center United States (USA) (US) Providence Portland Medical Center United States (USA) (US) Inselspital, Universitätsspital Bern Switzerland (CH) Keio University Japan (JP) Radboud University Nijmegen Netherlands (NL) Sapporo Medical University / 札幌医科大学 Japan (JP) Yamaguchi University Japan (JP) Oregon Health and Science University (OSHU) United States (USA) (US) National Institute for Health and Medical Research / Institut national de la santé et de la recherche médicale (INSERM) France (FR) General University Hospital in Prague / Všeobecná Fakultní Nemocnice v Praze (VFN) Czech Republic (CZ) University of Toronto Canada (CA) Curandis Laboratories LLC United States (USA) (US) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) Humanitas Research Hospital / IRCCS Istituto Clinico Humanitas Italy (IT) Grigore T. Popa University of Medicine and Pharmacy / Universitatea de Medicină și Farmacie "Grigore T. Popa" (UMF Iași) Romania (RO) Azienda ospedaliero-universitaria Senese Italy (IT) Kindai University / 近畿大学 Japan (JP) Karolinska Institute Sweden (SE) Istituto di ricovero e cura a carattere scientifico (IRCCS) Italy (IT)

How to cite

APA:

Mlecnik, B., Torigoe, T., Bindea, G., Popivanova, B., Xu, M., Fujita, T.,... Galon, J. (2022). Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers, 14(18). https://dx.doi.org/10.3390/cancers14184346

MLA:

Mlecnik, Bernhard, et al. "Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study." Cancers 14.18 (2022).

BibTeX: Download